《新股消息》康基醫療(09997.HK)上限13.88元定價 一手中籤率僅9%
內地醫療器械公司康基醫療(09997.HK)公布招股結果,發售價定於13.88元,為上限定價(招股價介乎12.36元至13.88元),公開發售錄超額認購988.22倍,每手500股,一手中籤比率僅為9%,認購90手即4.5萬股才可穩獲1手。該股將於下周一(29日)掛牌,高盛、中信證券及美銀證券為聯席保薦人。
公司預計集資淨額為29.56億元,當中20%將用於提升產能及加強製造能力;25%將用於研發活動提供資金;20%將用於投資銷售及營銷活動;25%用於為潛在戰略投資及收購提供資金;以及10%將用於營運資金及一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.